NEWS HIGHLIGHTSMedia Articles Related to Anturane (Sulfinpyrazone)
ASN: Febuxostat Works in Gout Patients with Renal Impairment (CME/CE)
Source: MedPage Today Rheumatology [2009.11.02]
SAN DIEGO (MedPage Today) -- In patients with gout and preexisting mild to moderate renal impairment, febuxostat (Uloric) is more effective and as safe as allopurinol, the gold standard gout treatment, researchers found.
ACR: Gout and Metabolic Disease Go Hand in Hand (CME/CE)
Source: MedPage Today Rheumatology [2009.10.27]
PHILADELPHIA (MedPage Today) -- Gout and hyperuricemia may represent another facet of metabolic syndrome, so closely tied are they to obesity, high cholesterol, and type 2 diabetes, suggested several studies presented here.
Low-Dose Colchicine (Colcrys) Is Rapid, Effective Treatment For Acute Gout Flares
Source: Gout News From Medical News Today [2009.10.26]
PHILADELPHIA - New data show that low-dose colchicine (ColcrysTM) rapidly controls acute gout flares. The results, which were presented at the 2009 Annual Scientific Meeting of the American College of Rheumatology, are drawn from a secondary analysis of the phase III Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial...
For Management Of Hyperuricemia In Patients With Gout, Uloric (Febuxostat) Demonstrated Efficacy
Source: Gout News From Medical News Today [2009.10.21]
Additional analysis showed that reduction and long-term maintenance of normal serum urate levels also reduced risk of future gout flares Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to A subset of subjects from the CONFIRMS trial who ...
New Data Presented At ACR Meeting Demonstrates Colcrys(TM) (Colchicine, USP) Significantly Reduces Pain Of Acute Gout Flare Within 24 Hours
Source: Gout News From Medical News Today [2009.10.20]
URL Pharma, Inc., announced data from a pivotal Phase III study demonstrating that Colcrys(TM) (colchicine, USP), a low-dose colchicine, reduced the pain of gout flares within a 24-hour period as effectively as high-dose colchicine with a side effect profile statistically indistinguishable from placebo...
Published Studies Related to Anturane (Sulfinpyrazone)
The effect of sulfinpyrazone on treadmill exercise-induced angina pectoris. [1993]
Suspecting that platelet thromboemboli could play a role in the pathogenesis of myocardial ischemia, we have done a random-order, double-blind, crossover study of the effect of the platelet-active drug sulfinpyrazone on treadmill exercise-induced angina pectoris in 30 men with coronary artery disease.
Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. [2000.12]
BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult. Because of the myelotoxicity of combined allopurinol and azathioprine, we tested sulfinpyrazone... However, this drug reduced CsA levels, thus the risk of rejection is present.
Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. [1998.08]
The protective activity of the phenylbutazone derivative, sulfinpyrazone on retinal lesions has been assessed in rabbits with severe streptozotocin-induced diabetes. Sulfinpyrazone (8 mg kg-1 per day per os) was administered in diabetic animals in two different experimental procedures: for 135 days in a preventive approach (beginning on the day of initial hyperglicaemia); and for 30 days in a therapeutic approach (beginning on the day of appearance of severe retinal damage)...
Acute renal failure due to sulfinpyrazone. [1998.05]
A case of sulfinpyrazone-associated acute renal failure is reported. Sulfinpyrazone can cause reversible acute renal failure from acute tubular necrosis in patients with volume depletion.The patients at risk for acute renal failure due to sulfinpyrazone are those who have intravascular volume depletion as sensed by the kidneys.
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. [1991.06.15]
We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis... A relatively high rate of complications, particularly mild gastrointestinal bleeding, was noted in patients on aspirin/sulfinpyrazone that could not be predicted on the basis of pre-treatment hemostatic test results.
|
